Welcome to our dedicated page for Polyrizon Ltd. SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. announced that the European Patent Office has completed technical preparations for publication of its European patent application EP 4751737 for mucoadhesive polymers used in nasal drug delivery. The application covers the company’s proprietary Trap & Target™ technology platform, designed to improve retention and absorption of drugs in the nasal cavity.
The publication is described as an important step in Polyrizon’s strategy to build its intellectual property portfolio and support future pharmaceutical collaborations in nasal drug delivery. The patent application remains under European examination, and any eventual grant could offer protection in multiple European markets but is not assured.
Polyrizon Ltd. has called its Annual General Meeting for July 13, 2026 in Raanana, Israel. Shareholders of record on June 15, 2026, when 2,083,979 ordinary shares were outstanding, may vote.
The agenda centers on governance and compensation: re-electing two Class II directors, approving an amended compensation policy, and authorizing new equity awards for directors, the chairman, CEO, and CTO. Proposals also seek higher annual fees for non-executive directors, a minimum NIS 3.5 per U.S. dollar exchange rate for converting the chairman’s pay, and re-appointment of Deloitte as auditor for 2026. The board unanimously recommends voting in favor of all proposals.
Polyrizon Ltd. reports clinical progress for its NASARIX™ (PL-14) program, signing agreements with two additional U.S. clinical sites and bringing the total to three major contracted centers for its upcoming trial. These sites are described as the largest and most strategically important in its planned multi-center study and are expected to provide the highest patient enrollment.
The trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, with up to five U.S. sites expected to participate. NASARIX™ is an intranasal hydrogel intended to form a protective barrier in the nasal cavity to block airborne allergens. The study will follow international Good Clinical Practice standards and support the company’s broader regulatory strategy.
Polyrizon Ltd. reports that it has extended negotiations for its proposed acquisition of a 51% stake in Arrow Aviation Ltd. The companies signed a letter agreement effective June 3, 2026, extending the MOU exclusivity and Initial Negotiation Period to June 30, 2026, while keeping all other MOU terms unchanged.
The report also states that this update is incorporated by reference into Polyrizon’s registration statements on Form S-8 and Form F-3 filed with the SEC.
Polyrizon Ltd. reported that its Board of Directors appointed Ami Oren as a Class I director, effective May 14, 2026. Oren, age 51, has over 20 years of experience founding and operating consumer-facing businesses, including Hummus Ami and prior catering and culinary ventures.
The report states that this information is incorporated by reference into Polyrizon’s existing Registration Statements on Form S-8 (File Nos. 333-284410 and 333-288923) and Form F-3 (File No. 333-291368), meaning those securities registration documents now include this updated board composition detail.
Polyrizon Ltd. reports that it has signed its first Clinical Trial Agreement with a U.S.-based allergy research site in Texas, advancing its PL-14 NASARIX™ Allergy Blocker program toward human clinical testing. This site will be the first center in a planned multi-center study in patients with seasonal allergic rhinitis.
The trial, titled “Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis,” will assess an intranasal spray designed to form a protective barrier against airborne allergens. The study is planned under international Good Clinical Practice standards as Polyrizon moves from development into potential clinical validation.
Polyrizon Ltd. filed a Form 6-K to share that it has submitted amended claims in its U.S. patent application covering its proprietary intranasal drug delivery platform. The new claims extend protection from the core mucoadhesive composition to related drug delivery systems and methods of use.
The expanded claim set focuses on compositions with sulfated polysaccharide polymers and additional polymers that form a continuous film on epithelial mucosa, aiming to improve delivery of active pharmaceutical ingredients. This step supports Polyrizon’s strategy to strengthen its global intellectual property around its intranasal hydrogel technologies, including its Capture and Contain and Trap and Target platforms.
Polyrizon Ltd. filed Amendment No. 1 to its Form F-1 registration statement to include a conformed signature for the independent auditor's consent and to update Part II (signatures and exhibit index). The prospectus (Part I) is unchanged.
The amendment is an exhibits-only filing and does not amend offering terms; it also discloses recent unregistered issuances and warrant/exercise activity, including private placements and registered direct offerings described in Part II.
Polyrizon Ltd. reports passive beneficial ownership disclosures from MMCAP International Inc. SPC and MM Asset Management Inc. The joint filing shows beneficial ownership increased to 136,525 ordinary shares as of 04/24/2026 (representing 7.3% of the class). The filing also reports the prior position of 100,247 shares as of 04/21/2026 (6.2%). The registrants state they hold shared voting and dispositive power over the disclosed shares and the filing is signed under a joint filing agreement.